Introduction
============

Gastric cancer (GG) is the second leading cause of cancer-related mortality and the fourth most common cancer globally[@B1]. Since the 1970s, there has been a persistent trend in the increasing percentage of proximal gastric cancer (PGC) with an associated decreasing percentage of distal gastric cancer (DGC) in western countries[@B2]-[@B6]. Epidemiological studies proposed that PGC seems to have different etiology and biological behavior from DGC[@B7].

Recent reports have demonstrated that PGC and DGC exhibit different clinicopathological and biological characteristics[@B8], [@B9]. For example, Fabio et al. [@B10] reported PGC were associated with more advanced tumor stage and older age; Kin et al. [@B8] found that PGC tended to have a poorly differentiated type than DGC. Moreover, data regarding prognosis in PGC versus DGC are conflicting. Some studies have reported a significantly shorter overall survival (OS) in PGC patients[@B10]-[@B12], whereas others found no significant differences in prognosis of PGC and DGC[@B9], [@B13]. Katsuhiko et al[@B14] even demonstrated a long-term survival in patients with PGC than in those with DGC.

As such, the aim of the present study is to investigate differences in clinicopathological characteristics, treatment strategies and prognosis of PGC in comparison with DGC, using the National Cancer Data Base (NCDB). We also sought prognostic factors in relation to the location of the primary lesion to aid in the selection of optimal adjuvant treatment for patients with GC.

Patients and Methods
====================

Data source
-----------

The NCDB is a national hospital-based registry jointly sponsored by the American College of Surgeons and the American Cancer Society. It collects data from more than 1,500 Commission on Cancer-accredited facilities and captures approximately 70% of incident cancers in the United States annually. The study was reviewed by the Yale Institutional Review Board and was exempt from review as a secondary data analysis.

Study population
----------------

The study population consisted of 97,060 patients who were diagnosed with GC from the years 2004-2015. This data set was limited to patients with gastric adenocarcinoma according to International Classification of Diseases for Oncology codes C16.0 to C16.9.

Study variables
---------------

The main exposure variable was PGC/DGC. PGC was defined as tumors with the epicenter located in cardia (C16.0) or fundus (C16.1), whereas DGC was defined as lesions of the body (C16.2), antrum (C16.3) or pylorus (C16.4). Other baseline patient/tumor characteristic variables that were collected included the age group (\<50, 50-64, 65-74, \>=75 years), sex (male, female), race (white, black), Hispanic ethnicity (non-Hispanic, Hispanic, other), facility type(non-academic, academic), insurance (uninsured, private insurance, Medicaid, Medicare, other, unknown), median income (\$) (\<38,000, 38,000-47,999, 48,000-62,999, 63,000+, unknown), circle distance (miles) (less than 50, greater than 50, unknown), Carlson-Deyo score (0, 1, 2, 3), clinical and pathologic TNM categories (as defined by the American Joint Committee on Cancer staging manual), number of nodes examined (0-15 nodes, \>15 nodes), number of nodes positive (0 nodes, 1-2 nodes, 3-6 nodes, 7-15 nodes, 16 or more nodes), scope of regional lymph node surgery (whether or not to underwent lymphadenectomy) (no, yes), and tumor grade (well, moderately, poorly, undifferentiated/anaplastic,). Characteristics of surgical treatment variables included type of gastrectomy (gastrectomy-partial, near-total/total gastrectomy, gastrectomy with esophagus, gastrectomy with other organs, gastrectomy (NOS), no surgery), and surgical margin (R0, R1, R2). Short-term outcome variables in secondary analyses included the following: surgical inpatient stay (days) (0-5, 6-7, 8-11, \>=12, unknown), 30-day unplanned readmission (no unplanned readmission, unplanned readmission, unknown). OS served as the primary endpoint of the study, and follow-up time was calculated based on the month.

Statistical analyses
--------------------

All analysis was done using SAS software v9.3 (SAS Institute, Inc., Cary, NC). Categorical variables were compared using Chi-square test while continuous variables were compared using student T-test. Kaplan-Meier and log-rand test was used to examine OS by GC subtype and treatment type. Cox-regression survival analysis was used to identify predictors of OS. The proportionality assumption of the cox-regression was checked by including a time-varying covariate, an interaction between the covariate and the event time. Hazard ratio (HR) and 95% confidence interval (CI) were used to measure the risk of death. A p-value less than 0.05 was considered statistically significant and all tests were two-sided.

Results
=======

Patient characteristics
-----------------------

Patient characteristics at time of diagnosis were summarized in supplementary Table [1](#SM0){ref-type="supplementary-material"}. Of the 97,060 GC patients, 60,513 (62.3%) were PGC and 36,547 (37.7%) were DGC. Patients diagnosed with GC had a mean age of 67.66 years with majority of them being male (68.95 %), white (80.31 %), and non-Hispanic (91.55 %). Compared to patients with DGC, patients with PGC were more likely to be younger (66.68 ± 12.45 years vs 69.28 ± 14.20, *p* \< 0.01), male (77.46% vs.54.85%, *p*\<0.01), and white (89.95% vs.64.34%, *p*\<0.01). Patients with PGC were also more likely to have private insurance, higher income, traveled a longer distance to hospitals, and be treated in academic hospitals compared to patients with DGC. Patients with PGC had lower Carlson scores, clinical and pathological TNM categories and the number of lymph nodes being examined and positive compared to patients with DGC. In terms of surgical treatment, PGC patients were less likely to have surgical treatment (36.61% vs. 51.97%, *p* \< 0.01) compared to DGC patients. Among surgically treated patients, a higher proportion of PGC patients received R0 resection, stayed longer in the hospital, and had no unplanned 30-day readmission compared to DGC patients.

Survival Outcomes
-----------------

Kaplan-Meier survival estimates for GC in different stages were shown in Figure [1](#F1){ref-type="fig"}A. The median survival time of patients with GC were 98.53 months in early stage, 29.7 months in locally advanced stage and 6.21 months in distant metastasis stage (*p*\<0.01) (Table [S1](#SM0){ref-type="supplementary-material"}). PGC patients in early stage had a significantly shorter survival compared with DGC patients (*p\<*0.01) (Figure [1](#F1){ref-type="fig"}B) with a median survival time of 91.83 months and 106.55 months respectively (supplementary Table [S2](#SM0){ref-type="supplementary-material"}). There were no significant differences (*p*=0.97) in OS between the two groups in locally advanced stage (Figure [1](#F1){ref-type="fig"}C). For patients with distant metastases, the PGC group had a longer survival compared with the DGC group (*p*\<0.01) (Figure [1](#F1){ref-type="fig"}D) with a median survival time of 13.85 months and 12.24 months respectively (supplementary Table [S2](#SM0){ref-type="supplementary-material"}).

Figure [1](#F1){ref-type="fig"}E and [1](#F1){ref-type="fig"}F showed the survival curves for PGC and DGC patients in locally advanced stage underwent gastrectomy according to different adjuvant therapy. Among locally advanced proximal gastric cancer (LAPGC) patients underwent gastrectomy, the median survival time were 20.63 months, 37.36 months, 32.13 months, and 37.16 months in gastrectomy alone group, neoadjuvant therapy (NAT) group, adjuvant therapy (AT) group, and NAT plus AT group, respectively (supplementary Table [S3](#SM0){ref-type="supplementary-material"}). Among locally advanced distal gastric cancer (LADGC) patients underwent gastrectomy, the median survival time were 21.36 months in gastrectomy alone group, 64.3 months in NAT group, 38.9 months in AT group, and 56.31 months in NAT plus AT group (supplementary Table [S3](#SM0){ref-type="supplementary-material"}).

Prognostic Factors
------------------

In multivariate analysis, DGC (HR, 1.07; 95% CI, 1.05-1.10; *p*\<0.01), local advanced stage (HR, 2.32; 95%, CI 2.21-2.43; *p*\<0.01), and distant metastatic stage (HR, 5.03;95% CI, 4.76-5.31; *p*\<0.01) were significant predictors for poor survival in GC patients (Table [2](#T2){ref-type="table"}). Compared to PGC, DGC was associated with improved survival in early stage (HR, 0.82; 95% CI, 0.74-0.91; *p*\<0.01) and local advance stage (HR, 0.94; 95% CI,0.90-0.97; *p*\<0.05), while DGC was associated with poor survival in distant metastatic stage (HR, 1.19; 95% CI,1.16-1.23; *p*\<0.01) (Table [3](#T3){ref-type="table"}).

In PGC patients with local advanced stage underwent gastrectomy (Table [4](#T4){ref-type="table"}), NAT (HR,0.80; 95%, CI 0.75-0.85; *p*\<0.01), AT (HR,0.79; 95%, CI 0.73-0.85; *p* \<0.01), and NAT plus AT (HR, 0.79; 95%, CI 0.72-0.87; *p*\<0.01) were all independent predictors of better OS, and no differences in survival between different adjuvant therapies were observed (*p*\>0.05). In DGC patients with local advanced stage underwent gastrectomy (Table [4](#T4){ref-type="table"}), subjects with NAT (HR, 0.62; 95%, CI 0.54-0.70; *p*\<0.01), AT (HR, 0.72; 95%, CI 0.68-0.77; *p*\<0.01), and NAT plus AT (HR, 0.61; 95%, CI 0.53-0.71; *p*\<0.01) had lower HRs than those underwent gastrectomy alone, and no differences in survival between NAT and NAT plus AT, but better survival of NAT or NAT plus AT than AT were observed.

After stratification by detailed adjuvant therapy, preoperative chemotherapy only (CT) (HR, 0.79; 95%, CI 0.71-0.87; *p*\<0.01), postoperative CT (HR, 0.84; 95%, CI 0.75-0.93; *p*\<0.01), pre- and post-operative CT (HR, 0.70; 95%, CI 0.60-0.82; *p*\<0.01), preoperative CT plus radiotherapy (RT) (HR, 0.80; 95%, CI 0.75-0.85; *p*\<0.01), preoperative CT plus RT and postoperative CT (HR, 0.79; 95%, CI 0.69-0.91; *p*\<0.01), postoperative CT plus RT (HR, 0.75; 95%, CI 0.70-0.82; *p*\<0.01), and preoperative CT and postoperative CT plus RT (HR, 0.73; 95%, CI 0.57-0.94; *p\<*0.01) were associated with improved survival in LAPGC patients underwent gastrectomy (Table [5](#T5){ref-type="table"}). Preoperative CT (HR, 0.57; 95%, CI 0.50-0.66; *p*\<0.01), postoperative CT (HR, 0.82; 95%, CI 0.75-0.90; *p*\<0.01), pre- and post-operative CT (HR, 0.50; 95%, CI 0.41-0.61; *p*\<0.01), postoperative CT plus RT (HR, 0.67; 95%, CI 0.62-0.72; *p*\<0.01), and postoperative CT plus RT (HR, 0.67; 95%, CI 0.62-0.72; *p*\<0.01) were associated with improved survival in LADGC patients underwent gastrectomy (Table [5](#T5){ref-type="table"}). Prognosis for patients treated with pre- and post-operative CT was significant better than for patients treated with other therapies in LAPGC and LADGC patients underwent gastrectomy.

Discussion
==========

Our study demonstrated that PGC was more common in younger patients similar to reports by Jun et al[@B15]. In contrast, several single institutional studies have shown PGC patients were older than DGC patients[@B4], [@B6], [@B9]. Other single institutional studies, however, have reported no association between age and tumor location[@B13], [@B16]. Analysis of different institutional databases has resulted in varying reports regarding the association between age at diagnosis and tumor location, primarily due to the limited sample size and non-representative samples.

PGC has very often been found to be inversely related to socioeconomic status (SES)[@B17], [@B18], whereas Linda et al. [@B19] shown that SES was not a statistically significant risk factor. Our study indicated that patients in PGC group had higher SES status reflected by higher income and private insurance. It could be due to a higher proportion of PGC patients in our study were white population. Whites were more likely to have high SES in America[@B20], [@B21].

Studies investigated prognosis of PGC and DGC have reported conflicting results with a majority of studies reporting a poorer survival in PGC[@B8], [@B10], [@B12], [@B15], one study reporting a worse prognosis in DGC patients[@B14], and two studies observing no significant differences[@B9], [@B13]. The reported variations of prognosis between PGC and DGC might be related to differences in stage and differentiated histology in different studies[@B8], [@B15]. Furthermore, several studies examining proximal gastric cancers included esophageal cancer in their analyses further confounding differences. While our study supported a better survival of PGC compared to DGC in overall population, we found that PGC patients in early stage or locally advanced stage had a worse prognosis compared with DGC patients in similar stage, whereas PGC patients with distant metastasis had better prognosis than DGC with distant metastasis. Although the reason for the observed difference in survival between PGC and DGC by stage is currently unclear, we speculate that the differences in tumor biology and anatomy between PGC and DGC play a role. The intraabdominal part of the cardia and fundus are not fully covered by visceral peritoneum perhaps making early PGC more prone to infiltrate the serosa and more inclined to peritoneal metastasis compared with early DGC[@B16]. GC with distant metastases is uniformly incurable and treated primarily with CT. Therefore, a possible reason for this result is that the response to CT differs between PGC and DGC. Katsuhiko et al.[@B14] reported that patients with PGC in distant metastasis stage had a significantly better response to CT than those with DGC.

The locally advanced stages are treated with multiple therapies[@B22]. Our study revealed a better prognosis for LAPGC and LADGC patients given additional therapy (NAT, AT, or NAT plus AT) as compared to gastrectomy alone. It is worth notice that NAT seems a useful treatment option for LADGC patients underwent gastrectomy with or without AT, whereas addition of NAT does not have any beneficial effect on survival in LAPGC patients underwent gastrectomy with AT. NAT is expected to improve the resection rate and long-term follow-up results by reducing the size of the primary lesion and controlling lymph node metastasis and micrometastasis[@B23]. Although PGC had a significantly better response to CT than DGC[@B14], various factors, such as stomach anatomy, different lymphatic metastasis path, and technical difficulties during surgery, could be potential explanation for the weak effect of NAT on PGC patients. During the past several years, there has been increasing awareness of the documented benefits from NAT in patients with localized gastric cancer. However, few studies are available concerning the survival outcomes of specific adjuvant therapy between PGC and DGC.

Postoperative CT is delivered with an intention to reduce recurrence by controlling residual tumor cells following curative resection. Recent advances in postoperative CT have achieved considerable tumor regression in many cases of gastric cancer[@B24]. Our results support that postoperative CT was associated with improved survival in LAPGC and LADGC patients. Although the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial has established Level 1 evidence for the perioperative CT[@B25], the addition of preoperative chemotherapy did not show any benefit in the trial by the European Organization for Research and Treatment of Cancer[@B26]. In our study, preoperative CT with or without postoperative CT showed OS benefit for PGC and DGC patients with locally advanced stage underwent gastrectomy. We also observed a significant OS benefit in favor of additional CT plus RT (preoperative CT plus RT, preoperative CT plus RT and postoperative CT, postoperative CT plus RT, and preoperative CT and postoperative CT plus RT) in LAPGC patients underwent gastrectomy, whereas only postoperative CT plus RT showed OS benefit in LADGC patients. While the underlying reasons remain unclear, these results warrant further investigation and highlight the importance of potential differences in response to adjuvant therapy between LAPGC and LADGC patients.

This study has several limitations that are typical to any large, retrospective database study. These include unidentified confounding factors, missing data, and potential coding errors. Additionally, the only available survival information is overall survival, which hampered the study to investigate relapse or disease-specific survival. The NCDB also does not provide information about completeness of adjuvant therapy. Despite these limitations, the NCDB provides a large sample size, making this study the largest study to date investigating the differences between PGC and DGC. It collects data from more than 1,500 Commission on Cancer-accredited facilities in the United States.

In summary, the study revealed that DGC was associated with older age, poorly differentiated histology, and advanced pTNM stage. Although PGC was associated with better prognosis compared to DGC, this observed better prognosis was only pronounced in patients with distant metastasis. PGC patients in early stage or locally advanced stage had a worse prognosis compared with DGC patients. A survival benefit was seen for LADGC patients underwent gastrectomy who received NAT or NAT plus AT compared with those who received AT only, whereas LAPGC patients did not share this result. Prognosis of LAPGC and LADGC varied by different forms of neoadjuvant and/or adjuvant therapy, and pre- and post-operative CT might be a recommended adjuvant treatment strategy for LAPGC and LAPGC. Although these findings in our study warrant further investigation to understand the underlying mechanisms, primary tumor location should be carefully considered when deciding treatment strategies.
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![(A) Kaplan-Meier survival analyses of all patients with different stages. (B) Kaplan-Meier survival analyses of PGC group and DGC group in early stage. (C) Kaplan-Meier survival analyses of PGC group and DGC group in locally advanced stage. (D) Kaplan-Meier survival analyses of PGC group and DGC group in distant metastasis stage. (E) Kaplan-Meier survival analyses of LAPGC with gastrectomy stratified according to different adjuvant therapy. (F) Kaplan-Meier survival analyses of LADGC with gastrectomy stratified according to different adjuvant therapy.](jcav10p3145g001){#F1}

###### 

Characteristics of Gastric Adenocarcinoma by Tumor Location

  Characteristic                             Total (97,060)                    PGC group(n=60,513)   DGC group (n=36,547)   P value                                 
  ------------------------------------------ --------------------------------- --------------------- ---------------------- ---------- ------- ---------- --------- ----------
  **Age**                                    67.66                             13.20                 66.68                  12.45      69.28   14.20      \<.0001   
  **Age (y)**                                                                                                                                                       
                                             \<50                              9037                  9.31                   5342       8.83    3695       10.11     
                                             50-64                             28703                 29.57                  19910      32.90   8793       24.06     
                                             65-74                             26594                 27.40                  17782      29.39   8812       24.11     
                                             \>=75                             32726                 33.72                  17479      28.88   15247      41.72     \<0.0001
  **Gender**                                                                                                                                                        
                                             Male                              66920                 68.95                  46873      77.46   20047      54.85     
                                             Female                            30140                 31.05                  13640      22.54   16500      45.15     \<0.0001
  **Race**                                                                                                                                                          
                                             White                             77946                 80.31                  54432      89.95   23514      64.34     
                                             Black                             11431                 11.78                  3492       5.77    7939       21.72     
                                             Other                             7683                  7.92                   2589       4.28    5094       13.94     \<0.0001
  **Hispanic ethnicity**                                                                                                                                            
                                             Non-Hispanic                      84059                 86.61                  54135      89.46   29924      81.88     
                                             Hispanic                          7760                  8.00                   2949       4.87    4811       13.16     
                                             Unknown                           5241                  5.40                   3429       5.67    1812       4.96      \<0.0001
  **Insurance**                                                                                                                                                     
                                             Uninsured                         3404                  3.51                   1742       2.88    1662       4.55      
                                             Private Insurance                 30982                 31.92                  21343      35.27   9639       26.37     
                                             Medicaid                          6259                  6.45                   3145       5.20    3114       8.52      
                                             Medicare                          52886                 54.49                  31902      52.72   20984      57.42     
                                             Other                             1265.00               1.3                    943        1.56    322        0.88      
                                             Unknown                           2264                  2.33                   1438       2.38    826        2.26      \<0.0001
  **Median income (\$)**                                                                                                                                            
                                             \<38,000                          17258                 17.78                  9019       14.90   8239       22.54     
                                             38,000-47,999                     22216                 22.89                  14128      23.35   8088       22.13     
                                             48,000-62,999                     25720                 26.50                  16627      27.48   9093       24.88     
                                             63,000+                           30185                 31.10                  19750      32.64   10435      28.55     
                                             Unknown                           1681                  1.73                   989        1.63    692        1.89      \<0.0001
  **Circle distance (miles)**                                                                                                                                       
                                             Less than 50                      83870                 86.41                  50971      84.23   32899      90.02     
                                             Greater than 50                   11536                 11.89                  8577       14.17   2959       8.10      
                                             Unknown                           1654                  1.70                   965        1.59    689        1.89      \<0.0001
  **Facility type**                                                                                                                                                 
                                             Non-academic                      57028                 58.76                  35349      58.42   21679      59.32     
                                             Academic                          37638                 38.78                  23913      39.52   13725      37.55     
                                             Other                             2394                  2.47                   1251       2.07    1143       3.13      \<0.0001
  **Charlson score**                                                                                                                                                
                                             0                                 66532                 68.55                  42416      70.09   24116      65.99     
                                             1                                 21697                 22.35                  13061      21.58   8636       23.63     
                                             2                                 6209                  6.40                   3545       5.86    2664       7.29      
                                             3                                 2622                  2.70                   1491       2.46    1131       3.09      \<0.0001
  **Clinical T**                                                                                                                                                    
                                             T0                                1092                  1.13                   659        1.09    433        1.18      
                                             T1                                14016                 14.44                  8884       14.68   5132       14.04     
                                             T2                                9735                  10.03                  6578       10.87   3157       8.64      
                                             T3                                21472                 22.12                  16812      27.78   4660       12.75     
                                             T4                                7858                  8.10                   3915       6.47    3943       10.79     
                                             Unknown                           42887                 44.19                  23665      39.11   19577      53.57     \<0.0001
  **Clinical N**                                                                                                                                                    
                                             c0                                36270                 37.37                  21864      36.13   14406      39.42     
                                             c1                                22747                 23.44                  17175      28.38   5572       15.25     
                                             c2                                5048                  5.20                   3585       5.92    1463       4.00      
                                             c3                                2284                  2.35                   1490       2.46    794        2.17      
                                             Unknown                           30711                 31.64                  16399      27.10   14312      39.16     \<0.0001
  **Clinical M**                                                                                                                                                    
                                             c0                                71684                 73.86                  43961      72.65   27723      75.86     
                                             c1                                25376                 26.14                  16552      27.35   8824       24.14     \<.0001
  **CTNM**                                                                                                                                                          
                                             I                                 15513                 15.98                  9807       16.21   5706.00    15.61     
                                             II                                11262                 11.60                  7925       13.10   3337.00    9.13      
                                             III                               12388                 12.76                  9790       16.18   2598.00    7.11      
                                             IV                                26144                 26.94                  16826      27.81   9318.00    25.5      \<.0001
                                             Unknown                           31753                 32.71                  16165      26.71   15588.00   42.65     
  **Pathologic T**                                                                                                                                                  
                                             p0                                2053                  2.12                   1650       2.73    403        1.10      
                                             p1                                10230                 10.54                  6049       10.00   4181       11.44     
                                             p2                                9365                  9.65                   4897       8.09    4468       12.23     
                                             p3                                13943                 14.37                  8458       13.98   5485       15.01     
                                             p4                                5102                  5.26                   1344       2.22    3758       10.28     
                                             Unknown                           56367                 58.07                  38426      63.50   18492      50.60     \<0.0001
  **Pathologic N**                                                                                                                                                  
                                             p0                                18111                 18.66                  10693      17.67   7418       20.30     
                                             p1                                11336                 11.68                  6577       10.87   4759       13.02     
                                             p2                                5741                  5.91                   2756       4.55    2985       8.17      
                                             p3                                3918                  4.04                   1494       2.47    2424       6.63      
                                             Unknown                           57954                 59.71                  38993      64.44   18961      51.88     \<0.0001
  **Pathologic M**                                                                                                                                                  
                                             p0                                89051                 91.75                  56140.00   92.77   32911      90.05     
                                             p1                                8009                  8.25                   4373.00    7.23    3636       9.95      \<.0001
  **PTNM**                                                                                                                                                          
                                             I                                 13959                 14.38                  8251.00    13.64   5708.00    15.62     
                                             II                                12957                 13.35                  7762.00    12.83   5195.00    14.21     
                                             III                               5306                  5.47                   1923.00    3.18    3383.00    9.26      
                                             IV                                8009                  8.25                   4373.00    7.23    3636.00    9.95      
                                             Unknown                           56829                 58.55                  38204.00   63.13   18625.00   50.96     \<.0001
  **Number of nodes examined**                                                                                                                                      
                                             0-15 nodes                        75162                 77.44                  47814      79.01   27348      74.83     
                                             \>15 nodes                        17239                 17.76                  9392       15.52   7847       21.47     
                                             Other                             4659                  4.80                   3307       5.46    1352       3.70      \<0.0001
  **Number of nodes positive**                                                                                                                                      
                                             0 nodes                           18844                 19.41                  11108      18.36   7736       21.17     
                                             1-2 nodes                         8798                  9.06                   5284       8.73    3514       9.62      
                                             3-6 nodes                         6834                  7.04                   3585       5.92    3249       8.89      
                                             7-15 nodes                        5165                  5.32                   2236       3.70    2929       8.01      
                                             16 or more nodes                  1725                  1.78                   617        1.02    1108       3.03      
                                             Other                             55694                 57.38                  37683      62.27   18011      49.28     \<0.0001
  **Scope of regional lymph node surgery**                                                                                                                          
                                             No                                54512                 56.16                  36805      60.82   17707      48.45     
                                             Yes                               41193                 42.44                  22759      37.61   18434      50.44     
                                             Unknown                           1355                  1.40                   949        1.57    406        1.11      \<0.0001
  **Tumor grade**                                                                                                                                                   
                                             Well                              4345                  4.48                   2907       4.80    1438       3.93      
                                             Moderately                        26426                 27.23                  18040      29.81   8386       22.95     
                                             Poorly                            49420                 50.92                  28402      46.94   21018      57.51     
                                             Undifferentiated; anaplastic      1245                  1.28                   705        1.17    540        1.48      
                                             Unknown                           15624                 16.1                   10459      17.28   5165       14.13     \<0.0001
  **Stage**                                                                                                                                                         
                                             Early stage                       6619                  6.82                   3481       5.75    3138       8.59      
                                             LAGC                              28779                 29.65                  16479      27.23   12300      33.66     
                                             Distant                           28142                 28.99                  17777      29.38   10365      28.36     \<.0001
  **Type of gastrectomy**                                                                                                                                           
                                             Gastrectomy-partial               18382                 18.94                  18382      18.94   13526      37.01     
                                             Near-total or total gastrectomy   4098                  4.22                   4098       4.22    2007       5.49      
                                             Gastrectomy with esophagus        14288                 14.72                  14288      14.72   1496       4.09      
                                             Gastrectomy with other organs     3974                  4.09                   3974       4.09    1830       5.01      
                                             Gastrectomy, NOS                  408                   0.42                   408        0.42    136        0.37      
                                             No surgery                        55910                 57.6                   38358      63.39   17552      48.03     \<.0001
  **Surgical Margin**                                                                                                                                               
                                             R0                                36951                 38.07                  20969      34.65   15982      43.73     
                                             R1                                3332                  3.43                   1715       2.83    1617       4.42      
                                             R2                                2732                  2.81                   1283       2.12    1449       3.96      
                                             Unknown                           54045                 55.68                  36546      60.39   17499      47.88     \<.0001
  **Surgical Inpatient stay (days)**                                                                                                                                
                                             0-5                               8368                  8.62                   4423       7.31    3945       10.79     
                                             6-7                               7517                  7.74                   3031       5.01    4486       12.27     
                                             8-11                              12534                 12.91                  7386       12.21   5148       14.09     
                                             \>=12                             11637                 11.99                  7429       12.28   4208       11.51     
                                             Unknown                           57004                 58.73                  38244      63.2    18760      51.33     \<.0001
  **30-day unplanned readmission**                                                                                                                                  
                                             No unplanned readmission          91354                 94.12                  57231      94.58   34123      93.37     
                                             Unplanned readmission             3199                  3.3                    1769       2.92    1430       3.91      
                                             Unknown                           2507                  2.58                   1513       2.5     994        2.72      \<.0001

###### 

Multivariate analysis of GC after stratification by location and clinical stage.

                                                             Adjusted          
  -------------- -------------------- ------- ------- ------ ---------- ------ --------
  **Location**                                                                 
                 PGC                  54434   62.06   Ref                      
                 DGC                  33279   37.94   1.07   1.05       1.10   \<0.01
  **Stage**      57246                                                         
                 Early                6012    10.50   Ref                      
                 Local advanced       26126   45.64   2.32   2.21       2.43   \<0.01
                 Distant metastatic   25108   43.86   5.03   4.76       5.31   \<0.01

Adjust for age sex race Hispanic INSURANCE CDCC YEAR_OF_DIAGNOSIS income FLOC FTYPE distance grade RX_SUMM_SCOPE_REG_LN_SUR margin stay readm.

Abbreviations: GC, gastric cancer; PGC, proximal gastric cancer; DGC distal gastric cancer; HR, hazard ratio; CI, confidence interval.

###### 

Multivariate analysis between PGC and DGC after stratification by clinical stage

                                                        Adjusted          
  ------------------------ ----- ------- ------- ------ ---------- ------ --------
  **Early stage**                                                         
                           PGC   3157    52.51   ref                      
                           DGC   2855    47.49   0.82   0.74       0.91   \<0.01
  **Local advanced**                                                      
                           PGC   14857   56.87   ref                      
                           DGC   11269   43.13   0.94   0.90       0.97   \<0.01
  **Distant metastatic**                                                  
                           PGC   15801   62.93   ref                      
                           DGC   9307    37.07   1.19   1.16       1.23   \<0.01

Adjust for age sex race Hispanic INSURANCE CDCC YEAR_OF_DIAGNOSIS income FLOC FTYPE distance grade RX_SUMM_SCOPE_REG_LN_SUR margin stay readm

Abbreviations: PGC, proximal gastric cancer; DGC distal gastric cancer; HR, hazard ratio; CI, confidence interval.

###### 

Multivariate analysis of LAPGC and LADGC patients underwent gastrectomy after stratification by different adjuvant therapies.

                              PGC            DGC                                                                      
  ------------- ------------- ------ ------- ------ ------ ------ -------- ------ ------ ------- ------ ------ ------ --------
  **Therapy**   11478                                                      8749                                       
                No NAT/AT     2426   21.14   Ref                                  3643   41.64   Ref                  
                NAT           5652   49.24   0.80   0.75   0.85   \<0.01          677    7.74    0.61   0.54   0.70   \<0.01
                AT            2226   19.39   0.79   0.73   0.85   \<0.01          3932   44.94   0.72   0.68   0.77   \<0.01
                NAT plus AT   1174   10.23   0.79   0.72   0.87   \<0.01          497    5.68    0.61   0.53   0.71   \<0.01
                No NAT/AT                    1.25   1.17   1.33   \<0.01                         1.62   1.43   1.84   \<0.01
                NAT                          Ref                                                 Ref                  
                AT                           0.99   0.92   1.05   0.67                           1.62   1.43   1.84   0.02
                NAT plus AT                  0.10   0.91   1.08   0.82                           0.99   0.83   1.19   0.92
                No NAT/AT                    1.27   1.18   1.36   \<0.01                         1.39   1.31   1.48   \<0.01
                NAT                          1.01   0.95   1.08   0.67                           0.86   0.76   0.97   0,02
                AT                           Ref                                                 Ref                  
                NAT plus AT                  1.00   0.91   1.10   0.93                           0.85   0.73   0.98   0.03
                No NAT/AT                    1.26   1.15   1.39   \<0.01                         1.64   1.41   1.9    \<0.01
                NAT                          1.01   0.93   1.1    0.82                           1.01   0.84   1.21   0.92
                AT                           0.10   0.91   1.09   0.93                           1.18   1.02   1.36   0.03
                NAT plus AT                  ref                                                 ref                  

Adjust for age sex race Hispanic INSURANCE CDCC YEAR_OF_DIAGNOSIS income FLOC FTYPE distance grade RX_SUMM_SCOPE_REG_LN_SUR margin stay readm.

Abbreviations: LAPGC, locally advanced proximal gastric cancer; LADGC, locally advanced distal gastric cancer; HR, hazard ratio; NAT, neoadjuvant therapy; AT, adjuvant therapy.

###### 

Multivariate analysis of LAPGC and LADGC patients underwent gastrectomy after stratification by different detailed adjuvant therapies.

                                                   PGC            DGC                                                                  
  ------------- ---------------------------------- ------ ------- ------ ------ ------ -------- -- ------ ------- ------ ------ ------ --------
  **Therapy**                                                                                                                          
                No CT/RT                           2426   21.22   ref                              3643   41.64   ref                  
                Pre-op CT only                     888    7.77    0.79   0.71   0.87   \<0.01      580    6.63    0.57   0.50   0.66   \<0.01
                Post-op CT only                    669    5.85    0.84   0.75   0.93   \<0.01      1103   12.61   0.82   0.75   0.90   \<0.01
                Pre and post-operative CT only     355    3.10    0.70   0.60   0.82   \<0.01      312    3.57    0.50   0.41   0.61   \<0.01
                Pre-op RT only                     35     0.31    0.94   0.62   1.41   0.75        3      0.03    1.06   0.26   4.27   0.93
                Pre-op CT plus RT                  4729   41.36   0.80   0.75   0.85   \<0.01      94     1.07    0.85   0.65   1.11   0.23
                Pre-op RT and post-op CT           68     0.59    0.88   0.65   1.19   0.41        6      0.07    0.38   0.09   1.51   0.17
                Pre-op RT plus CT and post-op CT   438    3.83    0.79   0.69   0.91   \<0.01      20     0.23    0.57   0.29   1.15   0.12
                Post-op RT only                    78     0.68    1.07   0.83   1.38   0.61        115    1.31    1.05   0.85   1.31   0.65
                Pre-op CT and post-op RT           153    1.34    0.82   0.66   1.01   0.06        71     0.81    0.79   0.57   1.10   0.16
                Post-op CT plus RT                 1479   12.93   0.75   0.70   0.82   \<0.01      2714   31.02   0.67   0.62   0.72   \<0.01
                Pre-op CT and post-op RT plus CT   117    1.02    0.73   0.57   0.94   0.01        87     0.99    0.82   0.62   1.08   0.16

Abbreviations: LAPGC, locally advanced proximal gastric cancer; LADGC, locally advanced distal gastric cancer; HR, hazard ratio; CT, chemotherapy; RT, radiotherapy; Pre-op, preoperative; Post-op, postoperative.
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